Vertex Pharmaceuticals Incorporated (ETR: VX1)
Germany
· Delayed Price · Currency is EUR
377.20
+3.55 (0.95%)
Dec 20, 2024, 5:35 PM CET
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending September 30, 2024, with 11.61% growth. This brings the company's revenue in the last twelve months to $10.63B, up 10.06% year-over-year. In the year 2023, Vertex Pharmaceuticals had annual revenue of $9.87B with 10.51% growth.
Revenue (ttm)
$10.63B
Revenue Growth
+10.06%
P/S Ratio
n/a
Revenue / Employee
$1.97M
Employees
5,400
Market Cap
98.22B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVertex Pharmaceuticals News
- 1 day ago - Vertex wins approval of new cystic fibrosis therapy Alyftrek - Seeking Alpha
- 1 day ago - Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK⢠- GuruFocus
- 1 day ago - Vertex Pharmaceuticals Inc (VRTX) Announces FDA Approval of ALYFTREK for Cystic Fibrosis Treatment - GuruFocus
- 1 day ago - US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - Reuters
- 1 day ago - Vertex Pharmaceuticals Inc (VRTX) Expands TRIKAFTA® Approval for Cystic Fibrosis Treatment - GuruFocus
- 1 day ago - Vertex Pharmaceuticals (VRTX) Stock Surges Amid Mixed Analyst Ratings - GuruFocus
- 1 day ago - Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
- 1 day ago - Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants - Business Wire